The overall growth of the superdisintegrants
market is driven mainly by the increasing
adoption of orally disintegrating tablets (ODT),
growing generics market, and the emergence
of new superdisintegrants for the pharmaceutical industry. The shifting focus of
pharmaceutical manufacturing to emerging markets and the growth of the overall
pharmaceutical sector in these markets present significant opportunities for the
superdisintegrants
market growth.
However, safety and quality concerns are
expected to challenge the
market growth to a certain extent during the forecast period.
In
this report, the market is segmented by type, formulation, therapeutic area, and
region.
By type, the global superdisintegrants market is segmented into natural superdisintegrants, synthetic
superdisintegrants, and other superdisintegrants. Synthetic superdisintegrants accounted for the largest share of the superdisintegrants
market in 2017. The
large share
of this segment is attributed to the increasing number of companies manufacturing synthetic
superdisintegrants due to their widespread usage in various pharmaceutical
formulations.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=198068672
By formulation, the superdisintegrants
market is segmented into tablets and
capsules. The tablets segment accounted for the larger share of the superdisintegrants
market in 2017. The large
share of this segment can be attributed
to the widespread use of ODTs and fast-disintegrating tablets (FDTs) among
healthcare providers and patients, resulting in the large-scale manufacture of
these products by pharmaceutical manufacturers. The high demand for such ODTs
and FDTs can be attributed to their
advantages such as increasing drug bioavailability, better pregastric
absorption, ease of swallowing in patients with dysphagia, ease of
administration, and improved shelf life.
Based
on therapeutic area, the superdisintegrants market is segmented into gastrointestinal
diseases, neurological diseases, oncology, infectious diseases, cardiovascular
disease, hematological diseases, and inflammatory diseases. Neurological diseases accounted for the largest
share of the superdisintegrants market in 2017. This segment is also expected
to witness the highest growth during the forecast period. The large share
of the neurological diseases segment is
attributed to the extensive usage of superdisintegrants in the
formulation of ODTs for antidepressants, antipsychotics, antimigraine, and
sedatives used in the treatment of neurological conditions.
The
superdisintegrants market in the APAC region is expected to register the
highest CAGR during the forecast period. Several factors, such as the region’s
growing scientific base and capabilities, growth in the Asian pharmaceutical
markets and pharmaceutical manufacturing capabilities, and the large patient
pool are contributing to the growth of the superdisintegrants market in the
region. The region is witnessing an increasing number of investments by major
market players to leverage the high-growth opportunities provided by emerging
markets such as China and India.
Speak To Analyst @ https://www.marketsandmarkets.com/speaktoanalyst.asp?id=198068672
No comments:
Post a Comment